Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-10-11
2005-10-11
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S215000, C514S217010, C540S543000, C540S586000, C540S593000
Reexamination Certificate
active
06953787
ABSTRACT:
The present invention relates to novel compounds of Formula (I):which act as 5HT2Creceptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.
REFERENCES:
patent: 3652543 (1972-03-01), Hoegerle
patent: 3716639 (1973-02-01), Hoegerle et al.
patent: 3795683 (1974-03-01), Brossi et al.
patent: 4108989 (1978-08-01), Holden
patent: 4111957 (1978-09-01), Holden et al.
patent: 4233217 (1980-11-01), Shetty
patent: 4762845 (1988-08-01), Chu et al.
patent: 4988690 (1991-01-01), Effland et al.
patent: 5015639 (1991-05-01), Berger et al.
patent: 5691362 (1997-11-01), McCormick et al.
patent: 5750520 (1998-05-01), Danilewicz et al.
patent: 5856503 (1999-01-01), Aebi et al.
patent: 5861393 (1999-01-01), Danilewicz et al.
patent: 1090797 (1980-12-01), None
patent: 2197789 (1995-08-01), None
patent: 500 194 (1971-01-01), None
patent: 1944121 (1970-03-01), None
patent: 3315106 (1983-11-01), None
patent: 0 007 070 (1980-01-01), None
patent: 0 080 779 (1983-06-01), None
patent: 0 096 838 (1983-12-01), None
patent: 0 161 350 (1985-11-01), None
patent: 0 174 118 (1986-03-01), None
patent: 0285287 (1987-03-01), None
patent: 0285287 (1988-10-01), None
patent: 0 285 919 (1994-10-01), None
patent: 0 987 235 (2000-03-01), None
patent: 1 074 549 (2001-02-01), None
patent: 1221324 (1971-02-01), None
patent: 1225053 (1971-03-01), None
patent: 1268243 (1972-03-01), None
patent: 1 599 705 (1981-10-01), None
patent: 5339263 (1993-12-01), None
patent: 7807819 (1978-07-01), None
patent: WO 88/07858 (1988-10-01), None
patent: WO91/19698 (1991-12-01), None
patent: WO 93/00094 (1993-01-01), None
patent: WO95/13274 (1995-05-01), None
patent: WO96/04271 (1996-02-01), None
patent: WO96/05194 (1996-02-01), None
patent: WO96/33993 (1996-10-01), None
patent: WO98/06701 (1998-02-01), None
patent: WO98/40385 (1998-09-01), None
patent: PCT/JP02/02306 (2002-03-01), None
patent: WO 02/40471 (2002-05-01), None
patent: WO02/48124 (2002-06-01), None
patent: WO 02/074746 (2002-09-01), None
patent: WO03/000663 (2003-01-01), None
patent: WO 03/086306 (2003-10-01), None
Chang et al. (Bioorganic & Medicinal Chemistry Letters (1992), 2(5), 399-402). Abstract.
Fuchs, et al., “Total synthesis of (±)-Lennoxamine and (±)-Aphanorphine by Intramolecular electrophilic aromatic substitution reactions of 2-amidoacroteins,” Organic Letters, 2001, pp. 3923-3925, vol. 3, No. 24, American Chemical Society.
Orito, et al., “Benzolactams—I: Alkylation of 1,2,4,5-tetrahydro-3-methyl-3h-3-benzazepin-2-one with sodium hydride and alkyl halide,” Tetrahedron, 1980, pp. 1017-1021, vol. 36, Pergamon Press Ltd.
Orito, et al., “Synthetic studies of heterocyclic compounds I. Alkylation and acylation of 1,2,4,5-tetrahydro-3-methyl-3H-3-benzazepin-2-one,” CASREACT, 1979, 93:7990.
Pauvert, et al., “Silver nitrate-promoted ring enlargement of 1-tribromomethyl-1,2-dihydro-and 1-tribromomethyl-1,2,3,4-tetrahydro-isoquinoline derivatives: application to the synthesis of the anti-anginal zalebradine,” Tetrahedron Letters, 2003, pp. 4203-4206, vol. 44, Pergamon Press Ltd.
Ladd, et al., “Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 2-benzazepines, and 9-(Aminomethyl) fluorenes,” J. Med. Chem., 1986, pp. 1904-1912, vol. 29.
Orito, et al., “Total synthesis of pseudo type of protopine alkaloids,” Heterocycles, 1980, vol. 14, No. 1.
Pecherer, et al., The Synthesis of Some 7- and 7,8-substituted 2,3,4,5-tetrahydro-1H-3benzazepines, J. Heterocyclic Chemistry, 1971, 8(5), pp. 779-783.
Deady, et al., “Synthesis of some tetrahydro-2-and 3-benzazepines, and of hexahydro-3-benzazocine,” Journal of the Chemical Society, Perkins Transactions I, 1973, pp. 782-783.
Macdonald, et al., “Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))-phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): A Potent and selective dopamine D3Receptor Antagonist,” J. Med. Chem., 2003, 4952-4964, vol. 46, American Chemical Society.
NIDA Research Monograph 27, 1979; Problems of Drug Dependence, 1979; Proceedings of the 41st Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc.
Perry, et al., “Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men,” BMJ (1995) 310:560-564.
Greene and Wuts, Protective Groups in Organic Syntheses, 2nd Ed., Wiley and Sons, NY, 1991.
Tietze and Schimpf, “Efficient synthesis of 2,3,4,5-tetrahydro-1H-3-benzazepines by intramolecular Heck reaction,” Synthesis (1993) 9:876-880.
Gomber, et al., “Pharmacokinetics of a series of 6-chloro-2,3,4,5-tetrahydro-3-substituted -1H-3-benzazepines in rats,” Drug Metab. Disposition (1988) 16:367-372.
Chang, et al., “Dopamine receptor binding properties of some 2,3,4,5-tetrahydro-1H-3-benzazepine-7-ols with non-aromatic substituents in the 5-position,” Bioorg. Med. Chem. Lett. (1992) 2:399-402.
Hassine-Conlac, et al., “Preparation et properietes d'aldehydes dans la serie de la benzazapine-3,” Bull Soc. Chim. France (1971) 11:3985-3992.
Lennon, et al, “Azabenzocycloheptenones. Part XVIII. Amines and amino-ketones of the tetrahydro-3-benzazepin-1-one series,” J. Chem. Soc. Perkin Transacts. (1975) 7:622-626.
Schlademan and Partch, “Synthesis of oxo- and 1-hydroxy-azobenzocycloalkanes,” J. Chem. Soc. Perkin Transacts. (1972) 2:213-215.
Gardent and Hazebroucq, “Sur quelques de l'amino-2-bromo-4 1H benzazepine-3 et de ses derives,” Bull Soc. Chim. France (1968) 2:600-605.
Hazebroucq, Acces a des I-H, tetrahydro-2,3,4,5 benzazepines-3 one-1 et a des hexahydro imidazo isoquinoleines, Ann. Chim. (1966) I:221-254.
Smith Brian
Smith Jeffrey
Arena Pharmaceuticals Inc.
Goddard Christine A.
Kifle Bruck
O'Connor Cozen
Spruce Lyle W.
LandOfFree
5HT2C receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5HT2C receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5HT2C receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3459062